Molecular Docking and Drug-Likeness Profiling of Phytochemical from Murraya koenigii against Estrogen Receptor Alpha
Breast cancer remains a major health problem, particularly in estrogen receptor-positive disease in which estrogen receptor alpha (ER-α) is an important molecular target. Curry leaf (Murraya koenigii) contains diverse secondary metabolites with reported pharmacological activities, but the interaction of its phytochemicals with ER-α has not been comprehensively characterized in the present study framework. This study evaluated 20 phytochemicals from M. koenigii against ER-α using an in silico molecular docking approach. The ER-α structure (PDB ID: 3ERT) was prepared using AutoDock Tools, while test ligands were constructed and energy-minimized using MarvinSketch. Docking was performed with AutoDock4 using the validated grid parameters, and binding interactions were visualized with BIOVIA Discovery Studio Visualizer. The redocking validation produced an RMSD of 1.049 Å, supporting the applicability of the docking protocol. Eleven compounds showed binding energies approaching the reference ligand 4-hydroxytamoxifen; Murrayazoline (-10.68 kcal/mol) and Pyrayafoline D (-10.11 kcal/mol) showed the most favorable docking scores among the tested phytochemicals. Ten of the 11 selected compounds interacted with relevant ER-α binding-site residues, while Isomahanine did not directly interact with the key Glu353/Arg394 site. Swiss-ADME prediction further identified Koenimbine, O-Methylmurrayamine, and Koenine as the most favorable compounds in the combined drug-likeness assessment, although Koenine showed a saturation-related limitation. These findings provide an in silico basis for prioritizing M. koenigii phytochemicals for subsequent experimental validation.
Authors
- Viviana Idris
- Muhammad Nahrawi Udharaja
- Yasmin Fathina Saputra
- Iswahyudi Iswahyudi
Publication Details
- Journal
- Jurnal Riseta Naturafarm
- Published
- 2026-11-13
- DOI
- https://doi.org/10.70392/jrn.v3i2.31
- Primary Topic
- Computational Drug Discovery Methods
- Type
- article
- Field-Weighted Citation Impact
- 0.00